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Venous thromboembolism (VTE) following breast cancer chemotherapy is common. Chemotherapy-induced alterations in markers
of haemostasis occur during chemotherapy. It is unclear how rapidly this occurs, whether this is upregulated in patients developing
VTE and whether changes predict for VTE. Markers of haemostasis, functional clotting assays and vascular endothelial growth factor
were measured before chemotherapy and at 24h, 4 days, 8 days and 3 months following commencement of chemotherapy in early
and advanced breast cancer patients and in age- and sex-matched controls. Duplex ultrasound imaging was performed after 1 month
or if symptomatic. Of 123 patients, 9.8% developed VTE within 3 months. Activated partial thromboplastin time (APTT),
prothrombin time (PT), D-dimer, fibrinogen, platelet count, VEGF and fibrinogen were increased in cancer. Fibrinogen, D-dimer,
VEGF and tissue factor were increased, at baseline, in patients subsequently developing VTE. D-dimer of less than 500ngml
 1 has a
negative predictive value of 97%. Activated partial thromboplastin time, PT and thrombin–antithrombin showed significantly different
trends, as early as within 24h, in response to chemotherapy in patients subsequently developing VTE. Markers of coagulation and
procoagulants are increased, before chemotherapy, in patients who subsequently develop VTE. A group of patients at minimal risk of
VTE can be identified, allowing targeted thrombopropylaxis to the higher risk group.
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Venous thromboembolism (VTE) following breast cancer chemo-
therapy is not uncommon. In early breast cancer, VTE occurs
in 5–10% of patients receiving chemotherapy (Weiss et al, 1981;
Levine et al, 1988; von Tempelhoff et al, 1996), with a mortality
of 0.2–0.5% (Weiss et al, 1981; Clahsen et al, 1994). Venous
thromboembolism rises to approximately 18% in advanced
breast cancer (Goodnough et al, 1984), with a mortality of 9%.
Approximately two-thirds of all VTEs occur within 3 months of
commencing chemotherapy (von Tempelhoff et al, 1996; Seward
et al 1999); however, despite this, thromboprophylaxis is rarely
used (Kirwan et al, 2003).
Previous work has demonstrated a hypercoagulable state in
breast cancer patients, with elevated markers of coagulation,
including thrombin–antithrombin (TAT) (Falanga et al, 1998;
Ozyilkan et al, 1998), fibrinogen (Miller and Heilmann, 1988),
D-dimer (Blackwell et al, 2000; Oberhoff et al, 2000) and tissue
factor (TF) (Lwaleed et al, 1999; Ueno et al, 2000).
Several small studies have reported alterations in markers of
coagulation in response to breast cancer chemotherapy, which
support the development of a chemotherapy-induced hyper-
coagulable state (Canobbio et al, 1986; Rogers et al, 1988; Feffer
et al, 1989; Rella et al, 1996; Pectasides et al, 1999). Several
pathogenic mechanisms have been suggested such as increased
expression or release of procoagulants and cytokines from
damaged cells, a direct toxic effect on vascular endothelium or
upregulation of platelet or monocyte activity. Although it is widely
accepted that development of VTE is multifactorial, the increased
rate of chemotherapy-induced VTE occurring in advanced breast
cancer patients as compared with adjuvant patients suggests that
other mechanisms may be occurring in the former group. It has
been postulated that the direct toxic effect of chemotherapy on
cancer cells may lead to increase in circulating tumour cell
fragments or microparticles with associated procoagulant activity
(Dvorak et al, 1983).
To date, the speed of onset of biochemical alterations in
haemostasis remains to be elucidated. Moreover, no study has
related cancer load to haemostatic and circulating procoagulant
response to chemotherapy.
Preoperative D-dimer, prothrombin fragments 1 and 2 (PF1þ2)
and TAT have been shown to have some value in predicting
postoperative VTE in patients undergoing major orthopaedic
surgery (Bongard et al, 1994; Ginsberg et al, 1995; Cofrancesco
et al, 1997; Lowe et al, 1999); however, markers of hypercoagul-
ability and D-dimer were found to be of no use in predicting VTE
in acutely ill medical patients (Crowther et al, 2005). Preoperative
PF1þ2, TAT and soluble fibrin do not predict postoperative DVT
in colorectal cancer patients; however, postoperative (days 1–7)
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slevels predict DVT, before a clinical diagnosis has been made
(Iversen and Thorlacius-Ussing, 2002).
Although several studies have investigated haemostatic res-
ponses to chemotherapy at a biochemical level, no study to date
has related these to the development of VTE, with a view to
identifying patients at increased risk of thrombosis.
In this study, we prospectively followed advanced and
early breast cancer patients commencing chemotherapy to
establish early alterations in markers of haemostasis and
procoagulants. This study was undertaken to investigate the
effect of cancer burden on chemotherapy-induced changes in
biomarkers of haemostasis and to assess the utility of chemo-
therapy-induced changes in biomarker concentration in
predicting VTE.
MATERIALS AND METHODS
Patients
A total of 123 female patients (median age 52 (range 31–78) years)
commencing chemotherapy for breast cancer were recruited. Of
these, 87 were receiving adjuvant chemotherapy following curative
surgery, and 36 were receiving chemotherapy for radiographically
proven metastatic breast disease (Table 1). Patients were excluded
if they were on anticoagulants, had a past history of VTE or had
implanted vascular access devices.
Control subjects
Sixty-eight age-matched female controls (median age 48 (range
31–78) years) with no history of cancer acted as control subjects.
Protocol
A prospective cohort study was undertaken. Markers of haemo-
stasis (TAT, fibrinogen, D-dimer, platelet count), functional
clotting assays (prothrombin time (PT) and activated partial
thromboplastin time (APTT)) and procoagulants (TF, cancer
procoagulant (CP) and plasma vascular endothelial growth factor
(pVEGF)) were measured before chemotherapy and at 24h, 4 days,
8 days and 3 months following commencement of chemotherapy
in all patients. A clinical assessment for VTE was performed at the
same time points. Bilateral screening full-leg duplex ultrasound
imaging was performed by accredited vascular scientists (Society
of Vascular Technologists) in all patients 1 month following
commencement of chemotherapy, and repeated if symptoms
developed.
Blood sampling and analytical methods
Atraumatic venous blood sampling was performed at the
antecubital fossa, and all specimens were separated and stored
within 2h after being collected into tubes containing citrate and
ETDA as anticoagulants. Citrate and EDTA samples were
immediately taken onto ice, and serum samples were allowed to
clot at room temperature. All samples (except full blood count and
clotting screen) were centrifuged for 20min at 41C and 2500g, and
the plasma or serum was removed from the cells. Serum and
citrated plasma samples were then divided into 0.3ml aliquots.
Platelet-depleted plasma (PDP) was also prepared for the
analysis of VEGF as detailed: one of the citrated tubes was
immediately plunged into ice and taken to the laboratory where
the sample was centrifuged at 41C for 20min at 3500g. The
supernatant was removed and recentrifuged for 20min at 3500g at
41C following which the PDP was aliquoted and the last 0.5ml
discarded. All samples were stored at  801C until analysis.
Prothrombin time (normal range 9–13.5s), APTT (normal range
16.5–24.5s) and fibrinogen (normal range 1.5–5.0gl
 1)w e r e
assayed by standard laboratory methods on ACL 3000 (Instrumen-
tation Laboratory, Warrington, UK). Platelet count was measured
using the Advia 120 Haematology System (Bayer Diagnostic,
Newbury, UK). Serum TAT concentration was determined by a
microplate immunoenzymatic method (Enzygnost
s TAT micro
ELISA, Dade Behring, Marburg, Germany), with a sensitivity of
1mgml
 1. Plasma D-dimer samples were analysed by a quantitative
fully automated ELISA assay using the VIDAS
s D-Dimer
(bioMe ´rieux, Marcy l’Etoile, France) system, with a sensitivity of
45ngml
 1 and upper limit of normal of 500ngml
 1. Plasma TF was
analysed using an enzyme-linked immunosorbent assay (ELISA)
(American Diagnostica Inc., Greenwich, CT, USA), with a sensitivity
of 10mgml
 1. Cancer procoagulant was measured indirectly using a
three-stage chromogenic assay to assess CP activity as described by
Mielicki and co-workers (Mielicki et al, 1999). Platelet-depleted
plasma VEGF was analysed using an ELISA by R&D Systems
s
(Oxon, UK), with a sensitivity of 9mgml
 1.
Ethical approval
The study was approved by the South Manchester Local Research
Ethics Committee and all patients gave written informed
consent.
Statistical methods
Data on PT, APTT platelet count and fibrinogen was parametric
and thus reported as mean (confidence interval). Data on D-dimer,
TAT, TF, CP and pVEGF was parametric after log conversion
and so reported as geometric mean (confidence interval).
Comparative group analysis (early, advanced breast cancer and
controls) of prechemotherapy patient values was performed by
ANOVA, with further analysis of subgroups using Scheffe.
Comparative group analysis (VTE within 3 months, VTE free) of
patient values was performed by independent T-test. Changes in
patient serum or plasma values with chemotherapy as compared
with pretreatment values were performed by paired T-test;
however, to minimise errors induced by multiple tests, a
repeated-measures analysis (Greenhouse Geiser correction) to
compare trends over time in patients with and without VTE was
used. Comparative group analysis (VTE within 3 months, VTE
free) of changes in coagulation parameters with chemotherapy as
compared with pretreatment values were performed by analysis of
covariance. A significance of Po0.05 was used. Binary logistic
regression to identify predictors of VTE was also performed.
Analysis was performed on baseline data, and change from
baseline. Appropriate corrections were made for cancer stage
and age.
Table 1 Chemotherapy regimens used in breast cancer patients
Chemotherapy regimen Number of patients
Adjuvant regimens
5-Fluorouracil, epirubicin, cyclophosphamide 65
Cyclophosphamide, methotrexate, 5-fluorouracil 15
Epirubicin, cyclophosphamide 4
Epirubicin 3
Metastatic regimens
Docetaxol 15
Cyclophosphamide, methotrexate, 5-fluorouracil 8
Epirubicin, docetaxol 6
Vinorelbine, mitomycin 3
Epirubicin 2
5-Fluorouracil, epirubicin, cyclophosphamide 1
Vinorelbine, 5-fluorouracil 1
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Of 123 breast cancer patients receiving chemotherapy, 12 (9.8%)
patients developed VTE within 3 months of chemotherapy, of
which 8 (66.7%) were symptomatic. Six of 36 (17%) metastatic
breast cancer patients and 6 of 87 (6.9%) early breast cancer
patients receiving adjuvant chemotherapy developed VTE. Deve-
lopment of VTE was not related to age, menopausal status or
tumour receptor expression.
Baseline data: before chemotherapy
Before chemotherapy, both APTT and PT were prolonged in
advanced and early breast cancer patients, compared with controls
(P¼0.01 and 0.06 respectively, Table 2). D-dimer, fibrinogen, TF,
platelet count and pVEGF were all increased in advanced breast
cancer compared with controls. TAT showed a similar trend.
D-dimer, fibrinogen and pVEGF were increased in advanced breast
cancer compared with early breast cancer, with TAT showing a
similar trend. D-dimer and fibrinogen were increased in early
breast cancer compared with controls (Table 2).
Baseline data: development of VTE before chemotherapy
Before chemotherapy, fibrinogen, D-dimer, TF and pVEGF
were increased in patients who subsequently developed VTE
within 3 months (fibrinogen: 4.9 (3.0–6.9)gl
 1, 3.4 (3.2–3.7)gl
 1,
P¼0.002/0.1, D-dimer: 1655 (834–3273)ngml
 1, 727 (631–
836)ngml
 1, P¼0.003; TF: 274 (115–654)mgml
 1, 107 (86–
134)mgml
 1, P¼0.03; pVEGF: 27.8 (14.3–54.1)mgml
 1, 15.4
(13.5–17.7)mgml
 1, P¼0.01, VTE within 3 months and VTE free,
respectively) (independent T-test). Similar trends were found when
advanced breast cancer patients were analysed separately (fibrino-
gen: 4.1 (3.3–4.9)gl
 1, 6.9 (3.7–10.1)gl
 1, P¼0.01; D-dimer:
2769 (1578–4859)ngml
 1, 1148 (806–1634)ngml
 1, P¼0.03; TF:
271 (117–627)mgml
 1, 164 (125–215)mgml
 1, P¼0.13; pVEGF:
19.5 (15.8–24.1)mgml
 1, 49.6 (15.3–160.7)mgml
 1, P¼0.004,
VTE within 3 months and VTE free, respectively).
In both early and advanced breast cancer patients, prechemo-
therapy fibrinogen and D-dimer are predictors for the develop-
ment of VTE. A 1-g increase in fibrinogen doubles the risk of VTE
(P¼0.005), and every 1000ngml
 1 increase in D-dimer is
associated with a 1.8-fold increased risk of VTE (P¼0.005).
Utilising the clinical cutoff for D-dimer of 500ngml
 1,
thrombosis could be predicted with a sensitivity of 92%, although
specificity was low at 31%. However, most importantly, the
negative predictive value was 97%. This has significant clinical
relevance because nearly 30% of these breast cancer patients
commencing chemotherapy had a D-dimer less than 500, and can
therefore be almost guaranteed to be safe from VTE.
Biomarker response to chemotherapy
The mean or geometric mean (CI) of coagulation parameters at
baseline, 24h, 4 days, 8 days and 3 months following chemo-
therapy is given in Table 3, and for patients subdivided into those
developing VTE and remaining free of VTE, the values are given in
Tables 4 and 5, respectively.
Analysing all patients together, irrespective of subsequent
development of VTE, all molecules analysed showed a significant
trend over time (repeated-measures analysis), except D-dimer and
TF (repeated-measures analysis) (Table 3).
In patients with and without VTE, by 4 days following
chemotherapy, platelet count was reduced; however, it remained
within normal limits. Levels returned to baseline by 3 months
(Table 3).
Activated partial thromboplastin time showed a marked short-
ening within 24h of commencing chemotherapy; however, this
was more pronounced in patients subsequently developing VTE
(P¼0.002). Although the shortening in APTT was maintained up
to 3 months, the difference between those with and without VTE
was not apparent after 24h (Tables 4 and 5).
Conversely, PT demonstrated a prolongation in response to
chemotherapy, which at days 4 and 8 was more marked in patients
developing VTE (P¼0.06 and 0.04, respectively) (Tables 4 and 5).
When patients who subsequently developed VTE were com-
pared with patients who remained free of VTE, there was no
difference in the response to chemotherapy of fibrinogen, D-dimer,
CP and pVEGF (Tables 4 and 5).
Thrombin–antithrombin, in patients subsequently developing
VTE, demonstrated a significant increase within 24h in response
to chemotherapy, which returned to baseline within 4 days
(P¼0.02) (Tables 4 and 5). Interestingly, at this time point,
4 patients had TAT values greater than 10-fold the upper
confidence interval. Three out of these four patients subsequently
developed VTE.
Table 2 Baseline biomarker results before chemotherapy
Coagulation marker
Advanced breast
cancer
Early breast
cancer Control
P ANOVA (Scheffe-showing paired
comparisons)
APTT secs,
mean (CI) (n)
22.6 (21.4–23.7)* (26) 23.2 (22.6–23.7)
w (77) 20.7 (20.2–21.3)*
w (38) o0.001 (* 0.01,
wo0.001)
PT secs, mean (CI) (n) 11.7 (11.4–12.1) (26) 11.7 (11.5–11.8) (77) 11.4 (11.2–11.6) (38) 0.06
TAT mg/ml, geometric
mean (CI) (n)
9.2*
w (4.7–18.1) (14) 4.2* (2.8–6.4) (11) 4.2
w (2.6–6.7) (13) 0.05 (* 0.1,
w0.1)
Fibrinogen g/l,
mean (CI) (n)
4.5 (3.7–5.3)*
w (21) 3.3 (3.1–3.5)*
z (73) 2.7 (2.5–3.0)
wz (38) o0.001 (*o0.001,
wo0.001,
z0.05)
D-dimer ng/ml,
geometric mean (CI) (n)
1334.9 (969.5–1837.8)*
w (35) 668.7 (584.8–764.5)*
z (87) 287.9 (248.7–333.3)
wz (61) o0.001 (*o0.001,
wo0.001,
zo0.001 )
Platelet count  10
9/l,
mean (CI) (n)
326.7* (286.9–366.5) (36) 309.6 (293.0–326.2) (87) 278.6 (257.7–299.6)* (45) 0.04 (*0.05)
TF mg/ml, geometric
mean (CI) (n)
179.2 (139.9–229.6)* (36) 92.1 (67.8–125.1) (85) 52.5 (30.8–89.6)* (61) 0.001 (*0.001)
CP mU, geometric
mean (CI) (n)
28.3 (24.8–32.3)* (33) 33.1 (30.7–35.6)* (78) 28.8 (25.3–32.8) (27) 0.04 (*0.09)
pVEGF mg/ml, geometric
mean (CI) (n)
22.8 (17.6–29.4)*
w (35) 14.2 (12.1–16.6)* (86) 15.1 (12.7–17.9)
w (61) 0.004 (*0.01,
w0.03)
Analysis of the difference between groups used analysis of variance (ANOVA). Where differences were found, further analysis (between pairs of groups, with respective pairs for
each molecule marked with *,
w,
z and
y) was performed using Scheffe (95% confidence interval (CI)).
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chemotherapy in those with and without VTE at 3 months. Tissue
factor demonstrates a more marked decrease at 3 months,
compared with baseline in patients subsequently developing VTE
(P¼0.02), even when corrections are made for cancer stage
(Tables 4 and 5). Of these early alterations in coagulation in
response to chemotherapy, only the prolongation of PT is an
independent predictor for chemotherapy-induced thrombosis. The
absence of an increase of PT at 8 days, relative to baseline, has a
negative predictive power of 100%. As this occurs in 45% of
patients, these individuals could be identified as no-risk for
thrombosis on the basis of the change in PT at day 8.
DISCUSSION
This study supports previously published data on the frequency of
VTE in breast cancer chemotherapy, with a rate of 17% in
advanced breast cancer (Goodnough et al, 1984) and 8% (Weiss
et al, 1981; Levine et al, 1988; von Tempelhoff et al, 1996) in early
breast cancer patients receiving adjuvant therapy.
The increase in APTT and PT in breast cancer patients before
chemotherapy suggests a paradoxical prolongation of clotting
times, compared with non-cancer controls. Previous smaller
studies have not demonstrated such a prolongation, but in all
studies, the control groups were not matched to the study group.
(Canobbio et al, 1986; Parmar et al, 1990; Mielicki et al, 1999;
Oberhoff et al, 2000).
An increase in markers of the clotting system in advanced
cancer, compared with early breast cancer, and early breast cancer
compared with controls is demonstrated in this study by D-dimer
and fibrinogen, confirming previous studies (Falanga et al, 1998;
Blackwell et al, 2000; Oberhoff et al, 2000; Dirix et al, 2002).
However, unlike previous research, in our study, the early breast
cancer group has undergone complete tumour excision, but in
spite of this, D-dimer levels remain elevated, perhaps implying a
prolonged postoperative thrombotic response.
Elevated circulating TF levels in breast cancer have been
described previously (Lwaleed et al, 1999; Ueno et al, 2000).
Thrombocytosis has been described previously in cancer patients.
(Sun et al, 1979; Pedersen and Milman, 1996).
The elevated prechemotherapy TAT levels in advanced breast
cancer patients in this study support previous findings in breast
(Falanga et al, 1998; Donati and Falanga, 2001), lung (Gabazza
et al, 1992; Seitz et al, 1997) and colorectal cancer (Iversen et al,
1996; Iversen and Thorlacius-Ussing, 2002).
Consistent with previously published literature, pVEGF levels in
this study are significantly elevated in advanced breast cancer
patients (Adams et al, 2000). Interestingly, levels in the early breast
cancer group (following apparent complete surgical resection) are
comparable with controls. Previous literature report increased
levels in early breast cancer patients before surgery, implying a
resolution of elevated levels (Heer et al, 2001).
In this study, we have found, before chemotherapy, significantly
elevated levels of D-dimer and fibrinogen in patients who subse-
quently develop VTE. Both markers are predictive for increased
Table 3 Alterations in biomarker parameters induced by chemotherapy in breast cancer patients
Procoagulant/
adhesion molecule
Prechemo-
therapy (n)
Day 1 (post-
chemotherapy) (n)
Day 4 (post-
chemotherapy) (n)
Day 8 (post-
chemotherapy) (n)
3 months (post-
chemotherapy) (n)
Trend
over time
(repeated
measures,
GG)
APTT s, mean (CI) 23.0 (22.5–23.5) (103) 21.6 (21.1–22.0) (108) 21.4 (21.0–21.8) (107) 21.8 (21.3–22.3) (108) 21.0 (20.5–21.5) (100) Po0.001
PT s, mean (CI) 11.7 (11.5–11.8) (103) 11.9 (11.7–12.0) (108) 11.7 (11.6–11.9) (107) 11.9 (11.7–12.0) (108) 11.5 (11.3–11.7) (98) Po0.001
TAT mgml
 1,
geometric mean (CI)
6.6 (4.3–10.0) (25) 11.3 (5.9–21.4) (24) 6.6 (4.5–9.6) (24) 5.6 (4.0–7.8) (24) 4.9 (3.1–7.7) (20) P¼0.04
Fibrinogen gl
 1,
mean (CI)
3.6 (3.3–3.8) (94) 3.3 (3.0–3.5) (98) 3.2 (2.9–3.4) (99) 3.4 (3.2–3.7) (104) 4.1 (3.8–4.3) (91) Po0.001
D-dimer ngml
 1,
geometric mean (CI)
815.3 (707.8–939.3) (122) 845.1 (729.3–979.1) (115) 786.7 (673.7–918.7) (115) 788.8 (680.5–914.3) (116) 763.3 (650.9–895.2) (109) P¼0.4
Platelet count
 10
9l
 1 mean (CI)
314.6 (298.4–330.9) (123) 306.1 (287.2–325.0) (99) 263.3 (249.7–276.8) (108) 242.3 (227.3–257.2) (117) 310.0 (285.0–334.0) (112) Po0.001
TF mgml
 1,
geometric mean (CI)
112.3 (89.0–141.6) (121) 116.3 (91.2–148.2) (116) 97.8 (76.9–124.3) (113) 97.3 (77.3–122.4) (115) 94.1 (74.0–119.8) (107) P¼0.3
CP mU,
geometric mean (CI)
31.6 (29.6–33.7) (111) 36.4 (34.1–38.8) (109) 34.4 (32.2–36.7) (104) 32.0 (29.8–34.3) (108) 30.9 (28.8–33.1) (100) Po0.001
pVEGF mgml
 1,
geometric mean (CI)
16.4 (14.2–18.8) (120) 14.9 (13.2–16.9) (115) 16.3 (14.0–18.0) (112) 20.5 (18.3–13.0) (114) 21.6 (18.8–24.9) (106) Po0.001
Table 4 Alterations in biomarker parameters induced by chemotherapy in breast cancer patients developing VTE within 3 months of chemotherapy
Coagulation marker Prechemotherapy (n)
Day 1 (post-
chemotherapy) (n)
Day 4 (post-
chemotherapy) (n)
Day 8 (post-
chemotherapy) (n)
3 months (post-
chemotherapy) (n)
APTT secs, mean (CI) 22.2 (18.7–25.6) (9) 19.8 (18.2–21.3) (9) 21.1 (19.4–22.7) (11) 21.6 (19.4–23.7) (8) 21.0 (18.6–23.4) (9)
PT secs, mean (CI) 11.5 (11.0–12.0) (9) 11.9 (11.5–12.4) (11) 11.9 (11.4–12.4) (11) 12.1 (11.3–12.9) (9) 11.8 (10.9–12.6) (7)
TAT mgml
 1, geometric
mean (CI)
8.9 (2.4–32.5) (8) 28.6 (4.9–167.1) (8) 6.3 (2.4–16.4) (8) 5.2 (2.4–11.1) (8) 3.9 (2.5–5.9) (7)
Fibrinogen gl
 1 mean(CI) 4.9 (3.0–6.9) (7) 4.2 (2.5–5.9) (8) 4.2 (2.9–5.5) (10) 4.4 (3.0–5.7) (7) 5.6 (4.5–6.8) (8)
D-dimer ngml
 1,
geometric mean (CI)
1618.6 (979.0–2676.1) (12) 1653.1 (996.0–2743.8) (11) 1297.1 (585.2–2875.1) (11) 1301.9 (642.4–2638.6) (11) 966.7 (504.9–1850.8) (9)
Platelet count
 10
9l
 1 mean (CI)
342.5 (265.8–419.2) (12) 338.9 (246.4–431.4) (10) 269.6 (225.5–313.8) (11) 274.0 (216.8–331.2) (11) 386.2 (238.3–534.1) (10)
TF mgml
 1,
geometric mean (CI)
231.1 (104.1–513.2) (11) 228.7 (107.1–488.5) (10) 190.9 (96.9–376.4) (10) 192.9 (82.2–452.5) (10) 81.4 (22.9–289.5) (8)
CP mU, geometric mean (CI) 31.4 (26.6–37.1) (11) 35.7 (28.4–44.9) (11) 32.5 (26.3–40.1) (11) 28.2 (22.9–34.7) (11) 27.8 (21.2–36.5) (9)
pVEGF mgml
 1,
geometric mean (CI)
27.8 (14.3–54.1) (12) 19.5 (10.4–36.6) (11) 19.0 (9.4–38.3) (11) 23.4 (13.2–41.5) (11) 18.7 (13.7–25.5) (9)
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have been found to correlate with development of VTE following
elective neurosurgery (Sonaglia et al, 1999).
A population-based prospective study has demonstrated a strong,
positive relationship between D-dimer and development of future
VTE (Cushman et al, 2003). Elevated presurgery D-dimer, before
development of VTE, has been reported previously in patients
undergoing hip surgery (Bongard et al,1 9 9 4 ;C o F r a n c e s c oet al, 1997).
However D-dimer did not predict for VTE in medical or surgical
patients admitted to ICU (Crowther et al, 2005), or in two studies of
71 and 60 ovarian cancer patients undergoing surgery (Olt et al, 1990;
von Tempelhoff et al, 1997). In 50 early breast cancer patients
undergoing chemotherapy, von Tempelhoff et al (1996) reports an
elevated mean prechemotherapy D-dimer in the five patients
subsequently developing VTE. In a small study investigating the
anti-angiogenic compound SU5415 (an inhibitor of VEGF receptor 1
and 2), pretreatment TF levels were significantly elevated in the three
patients who subsequently developed VTE, compared with the 17
patients without VTE (Kuenen et al, 2002), supporting our findings.
To date, no study has found a clinically useful test for predicting
VTE; however, in this study, we demonstrate that a subgroup of
patients (approximately one-third) can be considered as with
minimal risk of VTE (D-dimer o500ngml
 1 prechemotherapy),
so that thromboprophylaxis can be targeted to a more precise
high-risk group.
The almost universal, significant response of the measured
molecules to breast cancer chemotherapy demonstrates that
chemotherapy has a significant effect on coagulation and supports
previous studies (Canobbio et al, 1986; Rogers et al, 1988; Feffer
et al, 1989; Rella et al, 1996; Pectasides et al, 1999).
A shortening of APTT, in response to chemotherapy, has
previously been reported; however, here we provide evidence that
this response occurs within 24h of commencing treatment and may
be influential in VTE development. Both Pectasides and Canobbio
(Canobbio et al, 1986; Pectasides et al, 1999) show shortening of
functional clotting assay times equivalent to our 3-month findings.
In lung cancer patients receiving chemotherapy, Gabazza et al
(1992) reports an early shortening of APTT (at days 2, 5 and 7
following treatment) and a slightly later shortening of PT (at days 5,
7 and 14 following treatment). The fact worthy of note in the
current study is that the shortening of APTT is more pronounced in
the group subsequently developing VTE. Interestingly, Lowe et al
(1999) report that a shortened preoperative APTT is the only
independent predictor for post-hip surgery DVT in a study of 480
patients. The marked prolongation of PT at 8 days, occurring only
in patients who subsequently develop VTE, has not been reported
previously. Our current study is the first to identify such early
alterations in functional clotting studies in response to breast
cancer chemotherapy and, more importantly, that these alterations
are more marked in patients subsequently developing VTE.
The finding that a lack of prolongation of PT from prechemo-
therapy to day 8 identifies a subgroup at no risk of VTE has
profound clinical importance. A simple clotting study before
commencement of treatment and at the 1-week outpatient
appointment may half the number of patients that require
thromboprophylaxis.
It is surprising that products of intravascular coagulation, such
as fibrinogen and D-dimer show no significant alteration in
response to chemotherapy in the prothrombotic VTE group.
The early changes we have demonstrated in clotting, particularly
those changes occurring within 24h (TAT and APTT), are too
rapid to be caused by immobility secondary to chemotherapy-
induced malaise, or biochemical and fluid alterations with emesis.
The peak onset of VTE following total hip replacement is 4 days
(Sikorski et al, 1981). The true time of onset for chemotherapy-
induced VTE would require more extensive screening than was
performed in this study; however, early haemostatic responses to
chemotherapy may further upregulate a haemostatic system that is
already induced, due to cancer and recent surgery. A small study of
16 advanced cancer patients treated with chemotherapy demon-
strated an increase in plasma fibrinopeptide A (cleaved from
fibrinogen by thrombin) within 45min of chemotherapy admin-
istration; however, this response was abolished in 8 patients given
a second course of chemotherapy when treatment was preceeded
by heparin infusion (Edwards et al, 1990).
In conclusion, our large prospective study was the first study to
look at early alterations in haemostasis following breast cancer
chemotherapy, and the first to screen for VTE and relate such
alterations to development of VTE. We have confirmed that
chemotherapy-induced alterations occur early, within 24h, of
chemotherapy. Early alterations in functional clotting assays are
more marked in patients subsequently developing VTE. Early use
of thromboprophylaxis, perhaps even a single dose administered
before chemotherapy, may abolish this rapid haemostatic
response. We also present a method of identifying a subgroup of
patients at minimal risk of VTE, thus allowing targeted
thromboprophylaxis. A trial of single-dose thromboprophylaxis
in this subset may be warranted.
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Table 5 Alterations in biomarkers induced by chemotherapy in breast cancer patients remaining free of VTE within 3 months of chemotherapy
Coagulation marker Prechemotherapy (n)
Day 1 (post-
chemotherapy) (n)
Day 4 (post-
chemotherapy) (n)
Day 8 (post-
chemotherapy) (n)
3 months (post-
chemotherapy) (n)
APTT s, mean (CI) 23.1 (22.6–23.6) (94) 21.8 (21.3–22.2) (97) 21.5 (21.1–21.9) (96) 21.8 (21.3–22.3) (99) 21.0 (20.5–21.5) (91)
PT s, mean (CI) 11.7 (11.6–11.9) (94) 11.9 (11.7–12.0) (97) 11.7 (11.6–11.9) (96) 11.8 (11.7–12.0) (99) 11.5 (11.3–11.7) (91)
TAT mgml
 1, geometric
mean (CI)
5.7 (4.0–8.0) (17) 7.1 (4.4–11.3) (16) 6.7 (4.5–10.2) (16) 5.8 (3.8–8.6) (16) 5.6 (2.8–11.2) (13)
Fibrinogen gl
 1, mean(CI) 3.4 (3.2–3.7) (87) 3.2 (2.9–3.4) (90) 3.1 (2.8–3.3) (89) 3.4 (3.1–3.6) (97) 3.9 (3.6–4.2) (83)
D-dimer ngml
 1,
geometric mean (CI)
756.6 (655.9–872.7) (110) 787.1 (677.5–914.5) (104) 746.3 (640.7–869.1) (104) 748.4 (646.1–867.0) (105) 747.2 (632.5–882.7) (100)
Platelet count
 10
9l
 1 mean (CI)
311.6 (295.2–328.0) (111) 302.4 (283.4–321.4) (89) 262.5 (248.1–277.0) (97) 239.0 (223.4–254.5) (106) 302.5 (279.6–325.5) (102)
TF mgml
 1, geometric
mean (CI)
104.4 (82.0–133.1) (110) 109.1 (84.5–140.9) (106) 91.7 (71.1–118.2) (103) 91.2 (71.8–115.7) (105) 95.3 (74.3–122.1) (99)
CP mU, geometric mean (CI) 31.6 (29.4–33.9) (100) 36.5 (34.1–39.1) (98) 34.6 (32.3–37.1) (93) 32.4 (30.1–34.9) (97) 31.2 (29.0–33.6) (91)
pVEGF mgml
 1,
geometric mean (CI)
15.4 (13.5–17.7) (108) 14.5 (12.9–16.4) (104) 16.0 (13.7–18.7) (101) 20.2 (18.0–22.7) (103) 21.9 (18.8–25.5) (97)
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